Increased expression of glucose transporter1 (GLUT1) has been reported in many human cancers. We hypothesized that the degree of GLUT1 might provide a useful biological information in gastric adenocarcinoma. RT-PCR and immunostaining were used to analyze GLUT1 expression in gastric cancer. RT-PCR showed GLUT1 expression was not largely detected in normal gastric tissue but was detected in cancerous gastric tissue of counterpart. By immunohistochemistry, GLUT1 protein was absent in normal gastric epithelium and intestinal metaplasia. 11 of 65 patients with gastric adenocarcinoma had specific GLUT1 immunostaining in a plasma membrane pattern with varied intensities. GLUT1 protein did not show any significant correlation with tumor stage and nodal metastasis (p+AD4-0.05 by Mann-Whitney test). However, the positive immunostaining for GLUT1 is associated with intestinal differentiation (p+AD0-0.003). Our results suggest that GLUT1 protein is associated with intestinal type of gastric cancer.
Adenocarcinoma/pathology ; Adenocarcinoma/chemistry+ACo- ; Adult ; Aged ; Female ; Gastric Mucosa/pathology ; Gastric Mucosa/chemistry+ACo- ; Human ; Intestines ; Male ; Metaplasia ; Middle Age ; Monosaccharide Transport Proteins/analysis+ACo- ; Neoplasm Proteins/analysis+ACo- ; Reverse Transcriptase Polymerase Chain Reaction ; Stomach Neoplasms/pathology ; Stomach Neoplasms/chemistry+ACo- ; Tumor Markers, Biological/analysis+ACo-

Increased expression of glucose transporter1 (GLUT1) has been reported in many human cancers. We hypothesized that the degree of GLUT1 might provide a useful biological information in gastric adenocarcinoma. RT-PCR and immunostaining were used to analyze GLUT1 expression in gastric cancer. RT-PCR showed GLUT1 expression was not largely detected in normal gastric tissue but was detected in cancerous gastric tissue of counterpart. By immunohistochemistry, GLUT1 protein was absent in normal gastric epithelium and intestinal metaplasia. 11 of 65 patients with gastric adenocarcinoma had specific GLUT1 immunostaining in a plasma membrane pattern with varied intensities. GLUT1 protein did not show any significant correlation with tumor stage and nodal metastasis (p+AD4-0.05 by Mann-Whitney test). However, the positive immunostaining for GLUT1 is associated with intestinal differentiation (p+AD0-0.003). Our results suggest that GLUT1 protein is associated with intestinal type of gastric cancer.
Adenocarcinoma/pathology ; Adenocarcinoma/chemistry+ACo- ; Adult ; Aged ; Female ; Gastric Mucosa/pathology ; Gastric Mucosa/chemistry+ACo- ; Human ; Intestines ; Male ; Metaplasia ; Middle Age ; Monosaccharide Transport Proteins/analysis+ACo- ; Neoplasm Proteins/analysis+ACo- ; Reverse Transcriptase Polymerase Chain Reaction ; Stomach Neoplasms/pathology ; Stomach Neoplasms/chemistry+ACo- ; Tumor Markers, Biological/analysis+ACo-

A 42-year-old female diagnosed with tuberous sclerosis was found to have multiple polyps in the fundus of stomach. On histologic examination, the lesions were hamartomatous polyps. In tuberous sclerosis, many lesions occur in multiple organs and there are several reports about the frequent association of hamartomatous polyps of the colon. However, gastric manifestation of tuberous sclerosis has not been established probably due to its asymptomatic nature. This is the first report of multiple gastric hamartomatous polyposis in patient with tuberous sclerosis.
Abdominal Pain/etiology ; Actins/analysis ; Adult ; Case Report ; Cecal Neoplasms/pathology ; Encephalomalacia/etiology ; Female ; Gastric Fundus/pathology ; Gastroscopy ; Hamartoma/genetics+ACo- ; Human ; Hyperplasia ; Nasopharyngeal Neoplasms/pathology ; Neoplasm Proteins/analysis ; Polyps/genetics+ACo- ; Protein Isoforms/analysis ; Stomach Neoplasms/genetics+ACo- ; Tuberous Sclerosis/pathology+ACo- ; Tumor Markers, Biological/analysis

A 42-year-old female diagnosed with tuberous sclerosis was found to have multiple polyps in the fundus of stomach. On histologic examination, the lesions were hamartomatous polyps. In tuberous sclerosis, many lesions occur in multiple organs and there are several reports about the frequent association of hamartomatous polyps of the colon. However, gastric manifestation of tuberous sclerosis has not been established probably due to its asymptomatic nature. This is the first report of multiple gastric hamartomatous polyposis in patient with tuberous sclerosis.
Abdominal Pain/etiology ; Actins/analysis ; Adult ; Case Report ; Cecal Neoplasms/pathology ; Encephalomalacia/etiology ; Female ; Gastric Fundus/pathology ; Gastroscopy ; Hamartoma/genetics+ACo- ; Human ; Hyperplasia ; Nasopharyngeal Neoplasms/pathology ; Neoplasm Proteins/analysis ; Polyps/genetics+ACo- ; Protein Isoforms/analysis ; Stomach Neoplasms/genetics+ACo- ; Tuberous Sclerosis/pathology+ACo- ; Tumor Markers, Biological/analysis

Medulloblastoma accounts for 20 to 25+ACU- of all intracranial neoplasms in children. The significance of the presence of isochromosome 17q (i(17q)), proliferative potential, apoptotic activity, and expression of c-erbB-2, bd-2, and p53 proteins in predicting long-term survival of patients with medulloblastomas was investigated. Twenty children were divided into two groups (favorable and poor outcome groups). Ten children with favorable outcome (FO) were disease-free during the follow-up period (median: 61.5 months). The other ten children with poor outcome (PO) died of disease progression, having a median survival of 18 months. Fluorescent in situ hybridization (FISH) for i(17q), terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL), and immunohistochemistry for Ki-67, c-erbB-2, bcl-2, and p53 proteins was performed in these patients. Nine out of 17 children showed i(17q). There was no difference in the rate of positive i(17q) between the FO and PO groups. The presence of i(17q) was not significantly related to biological factors that we investigated. Unlike the prominent presence of the proliferative potential and p53 expression in children with PO, apoptotic activity and expression of c-erbB-2 and bcl-2 had no correlation with the outcome.
Adolescence ; Apoptosis ; Brain Neoplasms/pathology ; Brain Neoplasms/mortality ; Brain Neoplasms/genetics+ACo- ; Cell Division ; Child ; Child, Preschool ; Chromosomes, Human, Pair 17/ultrastructure+ACo- ; Chromosomes, Human, Pair 17/genetics ; Comparative Study ; Disease-Free Survival ; Female ; Follow-Up Studies ; Genes, bcl-2+ACo- ; Genes, erbB-2+ACo- ; Genes, p53+ACo- ; Human ; In Situ Hybridization, Fluorescence ; In Situ Nick-End Labeling ; Infant ; Ki-67 Antigen/analysis ; Male ; Medulloblastoma/pathology ; Medulloblastoma/mortality ; Medulloblastoma/genetics+ACo- ; Neoplasm Proteins/analysis ; Prognosis ; Retrospective Studies ; Survival Analysis ; Treatment Outcome

Medulloblastoma accounts for 20 to 25+ACU- of all intracranial neoplasms in children. The significance of the presence of isochromosome 17q (i(17q)), proliferative potential, apoptotic activity, and expression of c-erbB-2, bd-2, and p53 proteins in predicting long-term survival of patients with medulloblastomas was investigated. Twenty children were divided into two groups (favorable and poor outcome groups). Ten children with favorable outcome (FO) were disease-free during the follow-up period (median: 61.5 months). The other ten children with poor outcome (PO) died of disease progression, having a median survival of 18 months. Fluorescent in situ hybridization (FISH) for i(17q), terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL), and immunohistochemistry for Ki-67, c-erbB-2, bcl-2, and p53 proteins was performed in these patients. Nine out of 17 children showed i(17q). There was no difference in the rate of positive i(17q) between the FO and PO groups. The presence of i(17q) was not significantly related to biological factors that we investigated. Unlike the prominent presence of the proliferative potential and p53 expression in children with PO, apoptotic activity and expression of c-erbB-2 and bcl-2 had no correlation with the outcome.
Adolescence ; Apoptosis ; Brain Neoplasms/pathology ; Brain Neoplasms/mortality ; Brain Neoplasms/genetics+ACo- ; Cell Division ; Child ; Child, Preschool ; Chromosomes, Human, Pair 17/ultrastructure+ACo- ; Chromosomes, Human, Pair 17/genetics ; Comparative Study ; Disease-Free Survival ; Female ; Follow-Up Studies ; Genes, bcl-2+ACo- ; Genes, erbB-2+ACo- ; Genes, p53+ACo- ; Human ; In Situ Hybridization, Fluorescence ; In Situ Nick-End Labeling ; Infant ; Ki-67 Antigen/analysis ; Male ; Medulloblastoma/pathology ; Medulloblastoma/mortality ; Medulloblastoma/genetics+ACo- ; Neoplasm Proteins/analysis ; Prognosis ; Retrospective Studies ; Survival Analysis ; Treatment Outcome

p27kip1 is a cyclin-dependent kinase inhibitor that regulates progression from G1 into S phase. Aberrations in cell cycle control are often observed in tumors d might even be necessary in tumor development. Recent reports showed that low 7kip1 expression is associated with poor prognosis in several tumors and ukemia. To investigate the expression of p27kip1 in malignant lymphomas and ucidate the role of p27kip1 as a possible prognostic indicator, the authors rformed an immunohistochemical staining of p27kip1 correlated with Ki-67 belling index and clinical parameters. p27kip1 expression was reduced variably most malignant lymphomas and inversely correlated with Ki-67 labelling index +AD0-0.0151). Regarding chemotherapeutic response, p271kip1 expression in the mplete remission group showed statistically significant difference in pression compared to the progressive disease group (p+AD0-0.0021). There were gnificant differences in survival between cases with low and high p27kip1 pression (p+AD0-0.0071). In a multivariate Cox analysis, p27kip1 expression was dependent prognostic factors as well as other known prognostic factors cluding age, grade, stage and chemotherapeutic response. In conclusion, the udy suggests that reduced expression of p27kip1 protein may play a role in the thogenesis and biologically aggressive behavior of malignant lymphomas.
Adolescence ; Adult ; Aged ; Antineoplastic Agents, Combined/therapeutic use ; Cell Cycle ; Cell Division ; Child ; Child, Preschool ; Comparative Study ; Female ; Follow-Up Studies ; Human ; Ki-67 Antigen/analysis ; Life Tables ; Lymphoma, Non-Hodgkin/pathology ; Lymphoma, Non-Hodgkin/mortality ; Lymphoma, Non-Hodgkin/drug therapy ; Lymphoma, Non-Hodgkin/chemistry+ACo- ; Male ; Microtubule-Associated Proteins/physiology ; Microtubule-Associated Proteins/analysis+ACo- ; Middle Age ; Neoplasm Proteins/physiology ; Neoplasm Proteins/analysis+ACo- ; Prognosis ; Proportional Hazards Models ; Survival Analysis ; Treatment Outcome

p27kip1 is a cyclin-dependent kinase inhibitor that regulates progression from G1 into S phase. Aberrations in cell cycle control are often observed in tumors d might even be necessary in tumor development. Recent reports showed that low 7kip1 expression is associated with poor prognosis in several tumors and ukemia. To investigate the expression of p27kip1 in malignant lymphomas and ucidate the role of p27kip1 as a possible prognostic indicator, the authors rformed an immunohistochemical staining of p27kip1 correlated with Ki-67 belling index and clinical parameters. p27kip1 expression was reduced variably most malignant lymphomas and inversely correlated with Ki-67 labelling index +AD0-0.0151). Regarding chemotherapeutic response, p271kip1 expression in the mplete remission group showed statistically significant difference in pression compared to the progressive disease group (p+AD0-0.0021). There were gnificant differences in survival between cases with low and high p27kip1 pression (p+AD0-0.0071). In a multivariate Cox analysis, p27kip1 expression was dependent prognostic factors as well as other known prognostic factors cluding age, grade, stage and chemotherapeutic response. In conclusion, the udy suggests that reduced expression of p27kip1 protein may play a role in the thogenesis and biologically aggressive behavior of malignant lymphomas.
Adolescence ; Adult ; Aged ; Antineoplastic Agents, Combined/therapeutic use ; Cell Cycle ; Cell Division ; Child ; Child, Preschool ; Comparative Study ; Female ; Follow-Up Studies ; Human ; Ki-67 Antigen/analysis ; Life Tables ; Lymphoma, Non-Hodgkin/pathology ; Lymphoma, Non-Hodgkin/mortality ; Lymphoma, Non-Hodgkin/drug therapy ; Lymphoma, Non-Hodgkin/chemistry+ACo- ; Male ; Microtubule-Associated Proteins/physiology ; Microtubule-Associated Proteins/analysis+ACo- ; Middle Age ; Neoplasm Proteins/physiology ; Neoplasm Proteins/analysis+ACo- ; Prognosis ; Proportional Hazards Models ; Survival Analysis ; Treatment Outcome

Following improvements in therapy for childhood malignancies, the striking increase in survival rate over the past 30 years has led to the increase risk of developing second malignant neoplasms (SMNs). We report a case of colorectal carcinoma as a SMN, following treatment for rhabdomyosarcoma. The patient was diagnosed with rhabdomyosarcoma of the urinary bladder at his age of three years, and developed adenocarcinoma in the colon 13 years later. Histologic examination of the surgical specimen revealed adenocarcinoma involving the rectosigmoid area with radiation colitis in its background. The tumor cells showed strong immunoreactivity for p53 protein, suggesting the role of irradiation and p53 mutation in carcinogenesis. This case emphasizes the need for dose observation in survivors of early childhood malignancies treated with radiation and multiagent chemotherapy.
Adenocarcinoma/pathology ; Adenocarcinoma/genetics ; Adenocarcinoma/etiology+ACo- ; Adolescence ; Antineoplastic Agents, Combined/therapeutic use ; Antineoplastic Agents, Combined/adverse effects+ACo- ; Bladder Neoplasms+ACo-/radiotherapy ; Bladder Neoplasms+ACo-/drug therapy ; Case Report ; Colitis/pathology ; Colitis/etiology ; Colorectal Neoplasms/pathology ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/etiology+ACo- ; Combined Modality Therapy ; Cyclophosphamide/adverse effects ; Cyclophosphamide/administration +ACY- dosage ; Doxorubicin/adverse effects ; Doxorubicin/administration +ACY- dosage ; Genes, p53 ; Human ; Male ; Neoplasm Proteins/analysis ; Neoplasms, Radiation-Induced/pathology ; Neoplasms, Radiation-Induced/genetics ; Neoplasms, Radiation-Induced/etiology+ACo- ; Neoplasms, Second Primary/etiology+ACo- ; Protein p53/analysis ; Radiation Injuries/pathology ; Radiation Injuries/etiology ; Radiotherapy/adverse effects+ACo- ; Rhabdomyosarcoma+ACo-/radiotherapy ; Rhabdomyosarcoma+ACo-/drug therapy ; Sigmoid Neoplasms/pathology ; Sigmoid Neoplasms/genetics ; Sigmoid Neoplasms/etiology ; Time Factors ; Vincristine/adverse effects ; Vincristine/administration +ACY- dosage

Following improvements in therapy for childhood malignancies, the striking increase in survival rate over the past 30 years has led to the increase risk of developing second malignant neoplasms (SMNs). We report a case of colorectal carcinoma as a SMN, following treatment for rhabdomyosarcoma. The patient was diagnosed with rhabdomyosarcoma of the urinary bladder at his age of three years, and developed adenocarcinoma in the colon 13 years later. Histologic examination of the surgical specimen revealed adenocarcinoma involving the rectosigmoid area with radiation colitis in its background. The tumor cells showed strong immunoreactivity for p53 protein, suggesting the role of irradiation and p53 mutation in carcinogenesis. This case emphasizes the need for dose observation in survivors of early childhood malignancies treated with radiation and multiagent chemotherapy.
Adenocarcinoma/pathology ; Adenocarcinoma/genetics ; Adenocarcinoma/etiology+ACo- ; Adolescence ; Antineoplastic Agents, Combined/therapeutic use ; Antineoplastic Agents, Combined/adverse effects+ACo- ; Bladder Neoplasms+ACo-/radiotherapy ; Bladder Neoplasms+ACo-/drug therapy ; Case Report ; Colitis/pathology ; Colitis/etiology ; Colorectal Neoplasms/pathology ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/etiology+ACo- ; Combined Modality Therapy ; Cyclophosphamide/adverse effects ; Cyclophosphamide/administration +ACY- dosage ; Doxorubicin/adverse effects ; Doxorubicin/administration +ACY- dosage ; Genes, p53 ; Human ; Male ; Neoplasm Proteins/analysis ; Neoplasms, Radiation-Induced/pathology ; Neoplasms, Radiation-Induced/genetics ; Neoplasms, Radiation-Induced/etiology+ACo- ; Neoplasms, Second Primary/etiology+ACo- ; Protein p53/analysis ; Radiation Injuries/pathology ; Radiation Injuries/etiology ; Radiotherapy/adverse effects+ACo- ; Rhabdomyosarcoma+ACo-/radiotherapy ; Rhabdomyosarcoma+ACo-/drug therapy ; Sigmoid Neoplasms/pathology ; Sigmoid Neoplasms/genetics ; Sigmoid Neoplasms/etiology ; Time Factors ; Vincristine/adverse effects ; Vincristine/administration +ACY- dosage